Premier Fund Managers’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$13.6M Buy
227,500
+13,000
+6% +$758K 0.96% 44
2025
Q4
$11.6M Buy
+214,500
New +$10.3M 0.67% 57
2025
Q2
Sell
-159,200
Closed -$9.55M 174
2025
Q1
$9.55M Sell
159,200
-27,100
-15% -$1.58M 0.36% 61
2024
Q4
$10.4M Buy
186,300
+16,100
+9% +$900K 0.37% 59
2024
Q3
$8.67M Buy
+170,200
New +$7.98M 0.31% 61
2021
Q2
Sell
-10,767
Closed -$682K 221
2021
Q1
$682K Sell
10,767
-219
-2% -$13.6K 0.03% 190
2020
Q4
$680K Sell
10,986
-149,864
-93% -$9.22M 0.03% 208
2020
Q3
$9.63M Buy
160,850
+128,250
+393% +$7.72M 0.55% 52
2020
Q2
$1.92M Buy
+32,600
New +$1.95M 0.12% 144

Other funds holding BMY

Premier Fund Managers's BMY Position: Q1 2026 in Review

Premier Fund Managers increased its Bristol-Myers Squibb (BMY) stake by 6.1% in Q1 2026, buying an estimated $758K and bringing the position to 227,500 shares worth $13.6M. The position accounts for 0.96% of the portfolio, ranked #44.

Premier Fund Managers first reported a position in BMY in Q2 2020 and has held it in 9 quarters since. 2,517 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Premier Fund Managers held 227,500 shares of Bristol-Myers Squibb worth $13.6M as of Q1 2026.
  • Premier Fund Managers bought 13,000 Bristol-Myers Squibb shares in Q1 2026, an estimated $758K.
  • Bristol-Myers Squibb made up 0.96% of Premier Fund Managers's portfolio in Q1 2026, its #44 holding.
  • Premier Fund Managers first reported a position in Bristol-Myers Squibb in Q2 2020 and has held it in 9 quarters since.
  • 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Premier Fund Managers's 13F filing for Q1 2026, filed 14 May 2026.